Q-omics provides the consensus-scored DENND2B profile across patient tissues and cancer cell-line models. DENND2B expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in ESCA. Among the 18 cancer types available for tumor–normal comparison, DENND2B is differentially expressed in 11, with the highest sampling consensus in UCEC. Additionally, DENND2B protein abundance shows 22,559 significant protein co-abundance associations, with the highest sampling consensus in UCEC. Together, these results highlight ESCA, and UCEC as cancer lineages where DENND2B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DENND2B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DENND2B survival associations across molecular data types. DENND2B RNA expression shows survival associations in the most cancer types (21), followed by mutation status (2) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DENND2B RNA expression–survival associations across cancer types. High DENND2B expression shows unfavorable associations in LUSC, LGG, LIHC and CESC, but favorable associations in ESCA and LUAD. The ESCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .006). Together, the overview and detailed table identify ESCA as the clearest survival context for DENND2B RNA expression.
This table summarizes DENND2B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in BLCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for DENND2B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DENND2B shows lower tumor expression in UCEC, BLCA, KIRC and COAD and higher tumor expression in CHOL and LIHC. The UCEC box plot shows higher DENND2B RNA expression in normal versus tumor tissue (log2 FC = −2.495, t-test p < 0.001).
This table shows molecular features associated with DENND2B in patient tissues and cancer cell lines. In patient samples, DENND2B shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set. In cancer cell lines, DENND2B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and BREAST.
